UBS Group’s Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 CLDI.WS Stock Holding History

UBS Group’s Portfolio CLDI.WS Stock Details CLDI.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-5,398	Closed	-$70	–	10726
2024 Q3	$70	Buy	5,398 +1,497	+38%	+$46	﹤0.01%	9200
2024 Q2	$109	Buy	3,901 +3,768	+2,833%	+$240	﹤0.01%	9151
2024 Q1	$7	Buy	+133	New	+$8	﹤0.01%	9130
2023 Q4	–	Sell	-80	Closed	-$18	–	10132
2023 Q3	$18	Sell	80 -2,709	-97%	-$495	﹤0.01%	9141
2023 Q2	$318	Sell	2,789 -310	-10%	-$25	﹤0.01%	8312
2023 Q1	$124	Sell	3,099 -1,901	-38%	-$148	﹤0.01%	9204
2022 Q4	$150	Buy	5,000 +3,425	+217%	+$128	﹤0.01%	10352
2022 Q3	$0	Hold	1,575	–	–	﹤0.01%	11133
2022 Q2	$0	Buy	1,575 +300	+24%	+$67	﹤0.01%	11146
2022 Q1	$0	Buy	1,275 +100	+9%	+$44	﹤0.01%	11084
2021 Q4	$1K	Buy	+1,175	New	+$663	﹤0.01%	10062

Other funds holding CLDI.WS

EAM

Exos Asset Management New York $2.32K AUM 108.13% 1-Year Est. Return

UBS Group's CLDI.WS Position: Q4 2024 in Review

UBS Group sold out of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) in Q4 2024, closing a stake of 5,398 shares — an estimated $70 sold.

UBS Group first reported a position in CLDI.WS in Q4 2021 and held it in 11 quarters. The position peaked at $1K in Q4 2021. 1 fund tracked by Wall St. Rank holds CLDI.WS as of Q4 2024.

UBS Group reported no remaining Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position as of Q4 2024 after selling out during the quarter.
UBS Group sold 5,398 Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 shares in Q4 2024, an estimated $70.
UBS Group first reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in Q4 2021 and held it in 11 quarters.
UBS Group's Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position peaked at $1K in Q4 2021.
1 fund tracked by Wall St. Rank held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 as of Q4 2024.

Based on UBS Group's 13F filing for Q4 2024, filed 14 Feb 2025.